Central Ohio Urology Group

The trials here

What the 15 trials at this site are about, from their registry records.

Conditions

• Prostate cancer8 trials
• Bladder cancer7 trials
• Childhood cancers1 trial

Phase

• Phase 37 trials
• Phase 1/23 trials
• Phase 23 trials
• Phase 2/31 trial

Status

• Recruiting7 trials
• Active, not recruiting6 trials
• Completed2 trials

Lead sponsor

• Janssen Research & Development, LLC5 trials
• Novartis Pharmaceuticals2 trials
• Sumitomo Pharma America, Inc.2 trials
• Cellvax Therapeutics Inc1 trial
• Curium US LLC1 trial
• and 4 more

Running trials

• Recruiting

  Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma

  NCT07265947· Phase 2· Tyra Biosciences, Inc· Source

  Contact: Lara Balick

• Recruiting

  A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

  NCT06919965· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

  NCT06855277· Phase 3· Novartis Pharmaceuticals· Source

  Contact: Sam Carey

• Recruiting

  Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

  NCT06780670· Phase 2/3· Novartis Pharmaceuticals· Source

  Contact: Sarah Faisal

• Recruiting

  FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer

  NCT06636682· Phase 2· Cellvax Therapeutics Inc· Source

  Contact: Ronney Abaza, MD

• Active, not recruiting

  A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)

  NCT06211764· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T

  NCT06134232· Phase 2· Dendreon· Source

  Contact: Benjamin Martin, MD

• Active, not recruiting

  A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC

  NCT05884398· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)

  NCT05714202· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

  NCT05316155· Phase 1/2· Janssen Research & Development, LLC· Source

• Active, not recruiting

  177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

  NCT05204927· Phase 3· Curium US LLC· Source

• Recruiting

  LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

  NCT04752722· Phase 1/2· enGene, Inc.· Source

  Contact: enGene clinical trials

• Active, not recruiting

  A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

  NCT02138734· Phase 1/2· ImmunityBio, Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Prostate cancer4 recruiting
• Bladder cancer3 recruiting
• Childhood cancers1 recruiting

Closed trials

• Completed

  Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate

  NCT05605964· Phase 3· Sumitomo Pharma America, Inc.· Source

• Completed

  A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX

  NCT05467176· Sumitomo Pharma America, Inc.· Source